Volume | 66,277 |
|
|||||
News | - | ||||||
Day High | 3.73 | Low High |
|||||
Day Low | 3.65 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AbCellera Biologics Inc | ABCL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.69 | 3.65 | 3.73 | 3.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
490 | 66,277 | $ 3.69 | $ 244,813 | - | 3.62 - 8.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:53:13 | 99 | $ 3.73 | USD |
AbCellera Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.05B | 289.36M | - | 38.03M | -146.4M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AbCellera Biologics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABCL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.85 | 4.31 | 3.62 | 3.86 | 1,415,480 | -0.12 | -3.12% |
1 Month | 4.54 | 4.7499 | 3.62 | 4.16 | 1,131,617 | -0.81 | -17.84% |
3 Months | 5.15 | 5.46 | 3.62 | 4.72 | 1,382,845 | -1.42 | -27.57% |
6 Months | 4.06 | 6.055 | 3.62 | 4.87 | 1,437,777 | -0.33 | -8.13% |
1 Year | 6.74 | 8.05 | 3.62 | 5.81 | 1,943,523 | -3.01 | -44.66% |
3 Years | 29.55 | 36.05 | 3.62 | 10.60 | 1,981,692 | -25.82 | -87.38% |
5 Years | 61.00 | 71.91 | 3.62 | 12.42 | 1,889,981 | -57.27 | -93.89% |
AbCellera Biologics Description
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. |